Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRDF Cardiff Oncology, Inc.

Trading 08-10 14:53:53 EDT

1.04

+0.04

+4.35%

High1.09	Low0.9523	Vol713.61K
Open0.9800	D1 Closing0.9919	Amplitude13.38%
Mkt Cap80.39M	Tradable Cap77.87M	Total Shares77.67M
T/O719.56K	T/O Rate0.95%	Tradable Shares75.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRDF","market":"US","secType":"STK","nameCN":"Cardiff Oncology, Inc.","latestPrice":1.035,"timestamp":1786388030756,"preClose":0.9919,"halted":0,"volume":713605,"delay":0,"changeRate":0.04345196088315346,"floatShares":75235000,"shares":77673000,"eps":-0.665507,"marketStatus":"Trading","change":0.0431,"latestTime":"08-10 14:53:53 EDT","open":0.98,"high":1.085,"low":0.9523,"amount":719560.033725,"amplitude":0.133784,"askPrice":1.04,"askSize":724,"bidPrice":1.03,"bidSize":1148,"shortable":3,"etf":0,"ttmEps":-0.665507,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1786392000000},"marketStatusCode":2,"adr":0,"listingDate":1059624000000,"exchange":"NASDAQ","adjPreClose":0.9919,"preHourTrading":{"tag":"盘前","latestPrice":0.98,"preClose":0.9919,"latestTime":"08:57 EDT","volume":43287,"amount":41371.2948567,"timestamp":1786366645730,"change":-0.0119,"changeRate":-0.011997,"amplitude":0.029943},"postHourTrading":{"tag":"盘后","latestPrice":0.9989,"preClose":0.9919,"latestTime":"19:58 EDT","volume":6214,"amount":6184.6397,"timestamp":1786147100829,"change":0.007,"changeRate":0.007057,"amplitude":0.010082},"volumeRatio":1.177781,"impliedVol":2.2245,"impliedVolPercentile":0.8645},"requestUrl":"/m/hq/s/CRDF/tweets","defaultTab":"tweets","newsList":[{"id":"2654032298","title":"Cardiff Oncology Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2654032298","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654032298?lang=en_us&edition=fundamental","pubTime":"2026-07-25 04:31","pubTimestamp":1784925065,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Incexpected to post a loss of16cents a share - Earnings PreviewCardiff Oncology IncCRDF.OQCRDF.Ois expected to  show a fall in quarterly revenue when it reports  results on July 27 (e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nL8N43Q25H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652241394","title":"Cardiff Oncology CEO Mani Mohindru Acquires 34,364 Shares Worth $50,002.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2652241394","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652241394?lang=en_us&edition=fundamental","pubTime":"2026-07-17 04:01","pubTimestamp":1784232101,"startTime":"0","endTime":"0","summary":"Cardiff Oncology CEO Mani Mohindru acquires 34,364 shares worth $50,002.62Cardiff Oncology CEO Mani Mohindru bought 34,364 common shares at $1.46, lifting direct holdings to 59,067 shares.He also acqu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDLZWs50:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cardiff Oncology CEO Mani Mohindru Acquires 34,364 Shares Worth $50,002.62","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651683384","title":"Cardiff Oncology Issues Warrants to Buy 9,303,136 Shares in Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2651683384","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651683384?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:02","pubTimestamp":1784116950,"startTime":"0","endTime":"0","summary":"Cardiff Oncology issues warrants to buy 9,303,136 shares in registered direct offeringCardiff Oncology launched a registered direct offering with warrants covering 9,303,136 common shares.Warrants pri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL3njctt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU0314104364.USD","BCDF","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","BK4112","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4585","BK4588","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210149790.SGD","CRDF","LU2095319765.USD","BK4139","SG9999014021.USD","LU2210150020.SGD","NDAQ","SG9999014039.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651507364","title":"Cardiff Oncology Announces $10 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2651507364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651507364?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:00","pubTimestamp":1784116800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nTUA5C0QL0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645570027","title":"Cardiff Oncology CEO Mani Mohindru acquires 24,703 common shares for $29,890.63","url":"https://stock-news.laohu8.com/highlight/detail?id=2645570027","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645570027?lang=en_us&edition=fundamental","pubTime":"2026-06-22 21:00","pubTimestamp":1782133244,"startTime":"0","endTime":"0","summary":"Cardiff Oncology CEO Mani Mohindru reported a purchase of 24,703 common shares at $1.21 each.His direct beneficial ownership rose to 24,703 shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL1R66Qf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cardiff Oncology CEO Mani Mohindru acquires 24,703 common shares for $29,890.63","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642763231","title":"Cardiff Oncology shareholders approve 2021 equity plan share increase to 15,150,000 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2642763231","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642763231?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:16","pubTimestamp":1781209000,"startTime":"0","endTime":"0","summary":"Cardiff Oncology held its annual shareholder meeting on June 11, 2026.Shareholders ratified BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.Investors authorized an amendment to the 2021 Equity Incentive Plan, lifting the share pool to 15,150,000 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL2WNGbT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640863781","title":"Cardiff Oncology Cut to Hold From Buy by Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2640863781","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640863781?lang=en_us&edition=fundamental","pubTime":"2026-06-04 01:49","pubTimestamp":1780508940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRDF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 03, 2026 13:49 ET (17:49 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640218584","title":"Cardiff Oncology downgraded to Hold from Buy at Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2640218584","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640218584?lang=en_us&edition=fundamental","pubTime":"2026-06-04 00:07","pubTimestamp":1780502855,"startTime":"0","endTime":"0","summary":"Craig-Hallum downgraded Cardiff Oncology (CRDF) to Hold from Buy with a $2 price target Published first on TheFly – the ultimate source for real-ti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cardiff-oncology-downgraded-to-hold-from-buy-at-craig-hallum-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cardiff-oncology-downgraded-to-hold-from-buy-at-craig-hallum-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640949984","title":"Cardiff Oncology announces results from CRDF-004 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640949984","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640949984?lang=en_us&edition=fundamental","pubTime":"2026-06-02 22:11","pubTimestamp":1780409475,"startTime":"0","endTime":"0","summary":"Cardiff Oncology (CRDF) announced results from CRDF-004, a randomized, controlled, dose-finding Phase 2 clinical trial evaluating onvansertib in co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cardiff-oncology-announces-results-from-crdf-004-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cardiff-oncology-announces-results-from-crdf-004-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640945684","title":"BRIEF-Cardiff Oncology Announces Presentation Of Positive Results From Its Randomized, Controlled Phase 2 Trial Of Onvansertib In First-Line RAS-Mutated mCRC At The 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640945684","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640945684?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:12","pubTimestamp":1780405936,"startTime":"0","endTime":"0","summary":"BRIEF-Cardiff Oncology Announces Presentation Of Positive Results From Its Randomized, Controlled Phase 2 Trial Of Onvansertib In First-Line RAS-Mutated mCRC At The 2026 ASCO Annual MeetingJune 2 (Reu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA64ZNXV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640694556","title":"Cardiff Oncology says Phase 2 trial shows 72.2% response rate for onvansertib combo in first-line RAS-mutated mCRC","url":"https://stock-news.laohu8.com/highlight/detail?id=2640694556","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640694556?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:08","pubTimestamp":1780405736,"startTime":"0","endTime":"0","summary":"Cardiff Oncology disclosed positive Phase 2 results for onvansertib with standard chemotherapy in first-line RAS-mutated metastatic colorectal cancer.Data were presented at the 2026 ASCO Annual Meeting, showing improved tumor response and longer disease control versus standard-of-care alone.Safety profile remained consistent with standard treatment, with no new or additive toxicities reported.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL1K05qg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4585","SG9999014005.SGD","CRDF","SG9999014039.USD","BK4588","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU0314104364.USD","BK4112","SG9999014021.USD","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640945826","title":"Cardiff Oncology - Median Pfs Not Reached in Onvansertib Plus Folfiri/Bevacizumab Arms","url":"https://stock-news.laohu8.com/highlight/detail?id=2640945826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640945826?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:06","pubTimestamp":1780405560,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA64ZNXV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640945538","title":"Cardiff Oncology - 30 Mg Onvansertib Plus Folfiri/Bevacizumab Arm Shows Orr of 72.2% VS 42.1% for Soc","url":"https://stock-news.laohu8.com/highlight/detail?id=2640945538","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640945538?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:06","pubTimestamp":1780405560,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA64ZNXV:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640894558","title":"Cardiff Oncology - Onvansertib Safe and Well-Tolerated With No New Toxicities Added to Soc","url":"https://stock-news.laohu8.com/highlight/detail?id=2640894558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640894558?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:06","pubTimestamp":1780405560,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA64ZNXV:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640842945","title":"Cardiff Oncology Announces Presentation of Positive Results From Its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line Ras-Mutated Mcrc at the 2026 Asco Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640842945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640842945?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:06","pubTimestamp":1780405560,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA64ZNXV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640458299","title":"Cardiff Oncology - Phase 2 Trial Achieves Primary Goal Selecting Onvansertib Dose for Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2640458299","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640458299?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:06","pubTimestamp":1780405560,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA64ZNXV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640917774","title":"Kazia Therapeutics names James Levine CFO effective June 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2640917774","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640917774?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:30","pubTimestamp":1780399859,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics appointed James Levine as chief financial officer, effective June 1, 2026.Levine most recently served as CFO of Cardiff Oncology.He previously held CFO roles at Cidara Therapeutics, leading a USD 568 million licensing collaboration with Mundipharma.He also led a USD 780 million global partnership with Janssen Pharmaceuticals, following 12 years at Goldman Sachs as a managing director.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDLLQfTL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","LU2403377893.USD","LU2089984988.USD","SG9999002224.SGD","JNJ","IE00B3T34201.USD","LU1059921491.USD","SG9999013999.USD","IE00BGHQF631.EUR","LU1032955483.USD","IE00B4R5TH58.HKD","LU1023059063.AUD","BK4588","IE00B19Z3581.USD","LU1066051811.HKD","LU0345770308.USD","LU1121112475.USD","IE0034235303.USD","LU0203345920.USD","LU0053666078.USD","LU1032466523.USD","LU1066051225.USD","LU0070217475.USD","LU2896262040.SGD","IE00BBT3K403.USD","BK4559","IE00BFTCPJ56.SGD","LU1894683264.USD","LU1043141396.HKD","LU0345769128.USD","LU1551013425.SGD","LU1718418525.SGD","LU0912757837.SGD","LU0545562505.USD","IE00B19Z3B42.SGD","CRDF","LU2505996509.AUD","IE00BDGV0183.EUR","LU0234570918.USD","IE0000B7K699.USD","IE00B3PB1722.GBP","LU2456880835.USD","LU0964807845.USD","LU0210528500.USD","BK4568","KZIA","IE00B2B36J28.USD","LU1267930813.SGD","LU1221951129.SGD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640896483","title":"Cardiff Oncology to present at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2640896483","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640896483?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:01","pubTimestamp":1780344104,"startTime":"0","endTime":"0","summary":"Cardiff Oncology management will present at the Jefferies Global Healthcare Conference on June 4, 2026.CEO Mani Mohindru will lead a fireside chat scheduled for 10:30-11:00 a.m. ET on June 4.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL9vDmNt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","BK4112","IE00B64PRP62.GBP","NDAQ","IE00BN0W2W23.USD","LU0314104364.USD","LU2210149790.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4588","BK4139","SG9999014013.SGD","SG9999014005.SGD","CRDF","IE00BGHQF748.EUR","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640596959","title":"Cardiff Oncology Cut to Neutral From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2640596959","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640596959?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:48","pubTimestamp":1780314480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRDF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 01, 2026 07:48 ET (11:48 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640955714","title":"Cardiff Oncology Inc : H.c. Wainwright Cuts to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2640955714","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640955714?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:09","pubTimestamp":1780312151,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nFWN4290FZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cardiffoncology.com","stockEarnings":[{"period":"1week","weight":0.1596},{"period":"1month","weight":-0.2065},{"period":"3month","weight":-0.3952},{"period":"6month","weight":-0.3801},{"period":"1year","weight":-0.5884},{"period":"ytd","weight":-0.647}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.023989},{"month":2,"riseRate":0.5,"avgChangeRate":0.28397},{"month":3,"riseRate":0.357143,"avgChangeRate":0.075052},{"month":4,"riseRate":0.357143,"avgChangeRate":-0.062128},{"month":5,"riseRate":0.5,"avgChangeRate":0.055529},{"month":6,"riseRate":0.357143,"avgChangeRate":0.244554},{"month":7,"riseRate":0.4,"avgChangeRate":-0.096823},{"month":8,"riseRate":0.6,"avgChangeRate":0.104749},{"month":9,"riseRate":0.285714,"avgChangeRate":0.016213},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014863},{"month":11,"riseRate":0.357143,"avgChangeRate":0.032453},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.01141}],"exchange":"NASDAQ","name":"Cardiff Oncology, Inc.","nameEN":"Cardiff Oncology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cardiff Oncology, Inc.(CRDF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cardiff Oncology, Inc.,CRDF,Cardiff Oncology, Inc.股票,Cardiff Oncology, Inc.股票老虎,Cardiff Oncology, Inc.股票老虎国际,Cardiff Oncology, Inc.行情,Cardiff Oncology, Inc.股票行情,Cardiff Oncology, Inc.股价,Cardiff Oncology, Inc.股市,Cardiff Oncology, Inc.股票价格,Cardiff Oncology, Inc.股票交易,Cardiff Oncology, Inc.股票购买,Cardiff Oncology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cardiff Oncology, Inc.(CRDF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction